Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III NSCLC

Clinical trial NCT07139041 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07139041
Sponsor: Chang Chen
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC (Non-small-cell Lung Cancer)

Start date: 2025-10-01
Primary completion: 2027-04-01
Enrollment: 69

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.